Skip to main navigation Skip to search Skip to main content

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer

Research output: Contribution to journalArticlepeer-review

214 Citations (Scopus)

Abstract

Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body -positron emission tomography (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with ''operable'' non-small-cell lung cancer who underwent (18)FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET unsuspected malignant lesions in 10 (29%) Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body (18)FDG PET improves preoperative assessment of lung cancer patients.
Original languageEnglish
Pages (from-to)1265-1266
Number of pages2
JournalThe Lancet
Volume344
Issue number8932
DOIs
Publication statusPublished - 5 Nov 1994

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer'. Together they form a unique fingerprint.

Cite this